PTC/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sı	Substitute for form 1449A/B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known	
				Application Number	10/623,431
j				Filing Date	July 18, 2003
5				First Named Inventor	Jay D. KRANZLER
				Art Unit	1614
	(Use as many sheets as necessary)			Examiner Name	Rebecca COOK
Sheet	1	of	1	Attorney Docket Number	20269/1201776-US2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
11	BA	WO 02/053140 A2	07/11/2002	Pharmacia & Upjohn Co.		$\vdash$	
W/	ВВ	WO 00/32178	06/08/2002	Mueller			
11	BC_	EP 0 759 299 B1	04/26/2000	Eli Lilly and Company		Г	
	BD	WO 99/59593	11/25/1999	Eli Lilly and Company		Г	
ıλ	BE	FR 2 752 732	03/06/1998	Bruno et al.			
Ü	BF	WO 97/35584	10/02/1997	Eli Lilly and Company		Г	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
1	CA	RAO et al., The neuropharmacology of centrally-acting analgesic medications in fibromyalgia, Theum. Dis. Clin. N. Am. 28 (2002) 235-259.				
i	СВ	NINAN, M.D., Philip T., Use of Venlafaxine in Other Psychiatric Disorders, <i>Depression and Anxiety</i> 12(1) (2000) 90-94.				
	CC	NUTT et al., Potential Applications of Venlafaxine, Rev. Contemp. Pharmacother. 9 (1998) 321-331.				
W	CD	DWIGHT et al., An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia, Psychsomatics 39(1) (1998) 14-17.				
1	CE	GOODNICK et al., Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders, J. Clin. Psychiatry 54(1) (1993) 13-20.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner f	1 1 10101	Date	
	11 /1 /11/1/	1 1-7/1	10/10-
Signature	101 1000	Considered   -\forall	I(PI)II > I
	-		

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.